Unit
- Cell therapy: A medical treatment that involves the administration of living cells to repair, replace, or regenerate damaged tissues or organs. The cells can be of human origin (autologous or allogeneic) and are processed, expanded, or genetically modified before infusion.
- Historical milestones: The first successful bone marrow transplant in 1956 laid the foundation. Subsequent advances include chimeric antigen receptor T-cell (CAR-T) approvals in 2017, and ongoing research into induced pluripotent stem cells (iPSCs) and mesenchymal stromal cells (MSCs).
- Autologous vs. allogeneic: Autologous therapies use the patient's own cells, reducing rejection risk but requiring individualized manufacturing. Allogeneic therapies use donor cells, enabling off-the-shelf availability but posing immune compatibility challenges.
- Key therapeutic categories: Hematopoietic stem cell transplantation (HSCT) for blood cancers, CAR-T for lymphoid malignancies, MSCs for inflammatory and degenerative conditions, and iPSCs for personalized regenerative medicine.
- Manufacturing complexity: Cell therapies require specialized facilities with cleanrooms, controlled environments, and stringent quality testing. The process includes cell collection, processing, expansion, formulation, cryopreservation, and release testing.
- Regulatory classification: In the U.S., cell therapies are regulated as biologics under the Public Health Service Act. The FDA requires Investigational New Drug (IND) applications for clinical trials and Biologics License Applications (BLA) for market approval.
- Clinical workflow integration: Successful cell therapy programs require coordination among apheresis units, manufacturing labs, pharmacy, nursing, and clinical teams. Each step from vein-to-vein must be tracked with chain of identity and chain of custody.
- Economic considerations: Cell therapies are high-cost, often exceeding $400,000 per patient. Value-based payment models, outcomes-based contracts, and managed entry agreements are emerging to address affordability and access.
- Quality control and release criteria: Each cell therapy product must meet predefined specifications for viability, potency, sterility, and purity before release. Testing includes flow cytometry, endotoxin assays, mycoplasma detection, and functional assays. These criteria ensure patient safety and consistency across batches.
- Patient eligibility and screening: Candidates undergo rigorous evaluation including disease status, organ function, performance status, and infection screening. Exclusion criteria may include active infections, organ failure, or prior therapies. Proper selection minimizes risks and improves outcomes.
- Toxicity management and monitoring: Cell therapies can cause cytokine release syndrome, neurotoxicity, or graft versus host disease. Multidisciplinary teams use grading systems, tocilizumab, corticosteroids, and supportive care. Close monitoring during and after infusion is critical for early intervention.
Scope of Practice
Role: Cell Therapy Program Coordinator
Within scope:
- Scheduling patient apheresis and coordinating with collection centers
- Maintaining chain of identity documentation throughout the process
- Communicating with manufacturing facilities regarding product readiness
- Educating patients on treatment timelines and side effect management
- Updating electronic health records with product lot numbers and infusion dates
Outside scope:
- Performing apheresis or vein access procedures
- Modifying cell product manufacturing protocols
- Prescribing immunosuppressive or supportive medications
- Interpreting laboratory results for clinical decisions
- Administering the cell product infusion
Quick Revision
- Cell therapy uses living cells to treat diseases, with major categories including HSCT, CAR-T, MSCs, and iPSCs.
- Autologous and allogeneic approaches have distinct advantages and challenges in manufacturing and immune compatibility.
- Regulatory frameworks classify cell therapies as biologics requiring IND and BLA submissions.
- The care coordination role includes scheduling, documentation, and communication but excludes clinical procedures and product modification.